Search Results
Jul 12, 2026, 12:00 ET A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
program is about changing that."HDT-401 combines Riboxxim, a precisely engineered molecule licensed from Riboxx GmbH of Dresden, Germany, with HDT Bio's proprietary LION™ nucleic acid delivery platform. The LION™ platform has been evaluated in more than 6,000 patients across multiple clinical programs,
More news about: HDT Bio Corp.
Jul 10, 2026, 16:05 ET Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.Conference CallQ32 Bio's live conference call and webcast with accompanying slides will begin on Monday, July 13, 2026 at 8:00 a.m. E.T. To access a live or recorded webcast
More news about: Q32 Bio
Jul 09, 2026, 10:00 ET SAI-DA 1.0 | GEOTA Platform: Revolutionizing Drug R&D with Digital Computing Power
technological foundation to empower efficient industry R&D and earning widespread recognition from the market and clients.Today, Sanyou Bio's intelligent R&D blueprint undergoes a major upgrade—the GEOTA intelligent program tool matrix, a core module of SAI-DA, is officially released,
More news about: Sanyou Bio
Jul 08, 2026, 13:00 ET LBB Specialties and Ruby Bio Partner to Advance Market Readiness for Fermentation-Derived Emulsifiers
the relationship is on emulsifiers, Ruby Bio's broader platform spans additional food ingredient and specialty chemical applications, creating opportunities for future collaboration as market needs continue to evolve.For more information about Ruby Bio's Fermentation-Derived Emulsifier Platform,
More news about: LBB Specialties LLC
Jul 08, 2026, 13:00 ET LBB Specialties and Ruby Bio Partner to Advance Market Readiness for Fermentation-Derived Emulsifiers
the relationship is on emulsifiers, Ruby Bio's broader platform spans additional food ingredient and specialty chemical applications, creating opportunities for future collaboration as market needs continue to evolve.For more information about Ruby Bio's Fermentation-Derived Emulsifier Platform,
More news about: LBB Specialties LLC
Jul 07, 2026, 22:30 ET 遠端桌面軟體重大突破！AweSun 首創 AI MCP 伺服器引領智慧遠控
四大核心適用人群與應用場景AweSun 將新功能整合為實際生產力，滿足不同使用族群需求：IT 網管／運維工程師｜AI 智慧運維透過 MCP 伺服器串接 AI 工具，自動完成設備查詢、維護與遠端重啟，並支援 BIOS 級排錯，提升維運效率與穩定性。商務與行動辦公族｜跨平台高效連線Mac 與 Windows 跨平台互通，搭配免密遠控，一鍵快速連回辦公環境，多螢幕操作更流暢。設計師／創作者｜高畫質遠端創作支援高解
More news about: AweRay Pte.,Ltd
Jul 07, 2026, 16:44 ET Beyond K-Pop Spotlight: K-MUSIC NIGHT 2026 Celebrates Storytelling, Identity, and Cultural Exchange
@kccny on instagram.Artist BiosJohn Park (@johnparkgram)John Park is an R&B solo artist who has built a distinctive musical world of his own. He is known
More news about: Korean Cultural Center New York
Jul 06, 2026, 17:09 ET Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
offering. These forward-looking statements are based on Nuvation Bio's current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Nuvation Bio's actual results, performance or achievements to differ materially
More news about: Nuvation Bio, Inc.
Jul 06, 2026, 13:14 ET Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership with DCM BioServices
Reale, CEO of Surplus Solutions. "Pairing our equipment expertise with DCM Bio's technical service capabilities gives our customers a single partner across the full lifecycle of liquid handling and lab automation equipment. DCM Bio's deep expertise in this highly specialized field makes them an exceptional
More news about: DCM BioServices
Jul 06, 2026, 08:00 ET Matica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease Models
hybrid (zIFV). Matica Bio will execute the work at its purpose-built facility in College Station, Texas.This collaboration highlights Matica Bio's role as a trusted partner for complex, next-generation viral programs. With deep expertise across multiple virus and cell modalities including AAV,
More news about: Matica Biotechnology, Inc.
Jul 04, 2026, 11:25 ET Strategic Collaboration | Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnostics
concept to radiopharmaceutical candidate compounds.2. Developing a Differentiated Product Portfolio:By combining Sanyou Bio's extensive experience in innovative drug development and its strengths in AI-driven molecular discovery with Baiyunshan Xihe's standardized production
More news about: Sanyou Bio
Jul 02, 2026, 20:00 ET Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
and update its shareholders and the public as and when appropriate in accordance with relevant requirements.For more information about Brii Bio's HBV programs visit www.briibio.com.About Hepatitis BHepatitis
More news about: Brii Biosciences Limited
Jul 01, 2026, 08:00 ET ARTAN Bio Closes $1 Million Seed Round to Advance its tRNA Platform Toward Human Studies
Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biologyST. PETERSBURG, Fla., July 1, 2026 /PRNewswire/
More news about: ARTAN BIO
Jun 30, 2026, 16:41 ET NABJ Announces Executive Director Search Committee and Launch of National Search Process
mission and I look forward to helping identify leaders who will advance and strengthen its impact for years to come."Headshots and short bios for committee members are available upon request.NABJ's Executive Director search will proceed according to the following timeline:RFP
More news about: National Association of Black Journalists
Jun 30, 2026, 16:02 ET Halozyme Appoints David Ramsay as President Drug Delivery
settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®
More news about: Halozyme Therapeutics, Inc.
Jun 30, 2026, 13:00 ET Inductive Bio joins Anthropic's Connector Ecosystem for Life Sciences, Surfacing State-of-the-Art ADMET Prediction to Drug Discovery Scientists through Claude
do."The connector is designed around Inductive Bio's commitment to protecting scientists' data: chemical structures submitted through Claude are not retained or used to train Inductive's models.Scientists and teams interested in Inductive Bio's full suite of ADMET and pharmacokinetic (PK) models
More news about: Inductive Bio, Inc.
Jun 29, 2026, 08:33 ET Consano Bio Highlights Scientific Advisory Board for C-1101, a Potential First-in-Class, Non-Opioid Therapy in Development for Chronic Sciatica
C-1101 is highly aligned with that need, and I am pleased to support the company as it advances this important program."Members of Consano Bio's Scientific Advisory Board include:Susan Stewart, JD, LL.M, RAC, FRAPS, a regulatory affairs and quality assurance leader
More news about: Consano Bio
Jun 25, 2026, 23:58 ET Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
terms and conditions of repayment of Nuvation Bio's senior secured loan agreement, and the risks and uncertainties inherent in Nuvation Bio's business. Other risk factors include those that are discussed under the heading "Risk Factors" in Nuvation Bio's Quarterly Report on Form 10-Q for the quarter
More news about: Nuvation Bio, Inc.
Jun 25, 2026, 07:45 ET AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
advancing Entolasta, a next-generation TLR5 agonist designed for potential broader therapeutic applications, including oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, a contract development and manufacturing organization (CDMO), currently provides biomanufacturing services
More news about: Valion Bio, Inc.
Jun 25, 2026, 07:00 ET Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Notes. These forward-looking statements are based on Nuvation Bio's current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Nuvation Bio's actual results, performance or achievements to differ materially
More news about: Nuvation Bio, Inc.
Jun 24, 2026, 14:00 ET Biosidus Expands its International Footprint Through Strategic Partnership with Mubadala Bio in the UAE
sciences platform of Mubadala Investment Company, to introduce a portfolio of biologic therapies in the United Arab Emirates through DiabTec, Mubadala Bio's biologics platform.
More news about: Biosidus
Jun 24, 2026, 11:45 ET EBONY Announces the Return of STAMPED in Celebration of Black Music Month
artists whose rises continue to shape the industry."The 2026 STAMPED artists are curated by EBONY staffers Savannah Taylor and Kenyatta Victor, and bios are written by Wongo Okon, bringing a thoughtful editorial lens to each featured talent and their contributions to music and culture. The
More news about: EBONY
Jun 24, 2026, 06:00 ET Ole Henrik Bang-Andreasen Promoted to Partner at AVANT BIO
firm's investment efforts, identifying innovative companies and technologies, and supporting the growth of AVANT BIO's portfolio companies. Ole has also been instrumental in strengthening AVANT BIO's presence in Europe and expanding the firm's reach across the region's growing life sciences innovation ecosystem."I
More news about: AVANT BIO LLC
Jun 24, 2026, 03:58 ET EQT Life Sciences participates in RQ Bio's USD 115 million Series A financing
Forbion, Monograph and Wellington Management, alongside existing investors LifeArc, Oxford Science Enterprises and Oxford University Innovation, in RQ Bio's oversubscribed USD 115 million Series A financing RQ Bio is developing antibody therapies to prevent seasonal influenza in high-risk and immunocompromised
More news about: EQT
Jun 23, 2026, 09:11 ET Wheeler Bio Launches New Website Reflecting Expansion of Capabilities, Clients Served, and a Commitment to High-Science, High-Touch Biologics Manufacturing
The new website reflects Wheeler Bio's evolution into a fully integrated CDMO supporting programs from cell line development through cGMP Drug Substance and Drug Product manufacturing. Designed
More news about: Wheeler Bio, Inc.